Shares of Intrexon Corporation (NYSE:XON) have received a consensus recommendation of “Hold” from the eight research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $43.20.

XON has been the topic of a number of recent analyst reports. Northland Securities reissued a “buy” rating and issued a $27.00 price objective on shares of Intrexon Corporation in a research note on Friday, October 6th. Griffin Securities reissued a “buy” rating and issued a $55.00 price objective on shares of Intrexon Corporation in a research note on Friday, October 6th. BidaskClub raised shares of Intrexon Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. JMP Securities reissued an “outperform” rating and issued a $42.00 price objective on shares of Intrexon Corporation in a research note on Thursday, October 5th. Finally, Zacks Investment Research cut shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th.

Intrexon Corporation (NYSE XON) traded down 4.41% during midday trading on Wednesday, reaching $17.97. The company’s stock had a trading volume of 1,442,482 shares. The firm’s market cap is $2.17 billion. Intrexon Corporation has a 52 week low of $17.03 and a 52 week high of $32.90. The firm has a 50 day moving average price of $19.16 and a 200-day moving average price of $21.12.

Intrexon Corporation (NYSE:XON) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. The business had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.08%. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.42) earnings per share. On average, analysts forecast that Intrexon Corporation will post ($0.87) earnings per share for the current fiscal year.

In related news, Director Dean J. Mitchell bought 5,000 shares of the business’s stock in a transaction on Friday, August 11th. The shares were purchased at an average price of $18.33 per share, for a total transaction of $91,650.00. Following the completion of the transaction, the director now directly owns 18,103 shares of the company’s stock, valued at approximately $331,827.99. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert B. Shapiro bought 2,850 shares of the business’s stock in a transaction on Tuesday, August 22nd. The stock was bought at an average price of $17.50 per share, for a total transaction of $49,875.00. Following the transaction, the director now directly owns 43,157 shares of the company’s stock, valued at $755,247.50. The disclosure for this purchase can be found here. Insiders acquired 144,569 shares of company stock worth $2,719,429 in the last 90 days. Company insiders own 56.30% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Synovus Financial Corp boosted its position in Intrexon Corporation by 0.6% in the second quarter. Synovus Financial Corp now owns 33,613 shares of the biotechnology company’s stock valued at $810,000 after buying an additional 200 shares in the last quarter. Alliancebernstein L.P. boosted its position in Intrexon Corporation by 0.6% in the second quarter. Alliancebernstein L.P. now owns 32,610 shares of the biotechnology company’s stock valued at $786,000 after buying an additional 200 shares in the last quarter. Legal & General Group Plc boosted its position in Intrexon Corporation by 2.1% in the second quarter. Legal & General Group Plc now owns 18,843 shares of the biotechnology company’s stock valued at $454,000 after buying an additional 393 shares in the last quarter. CWM LLC boosted its position in Intrexon Corporation by 1.7% in the second quarter. CWM LLC now owns 36,143 shares of the biotechnology company’s stock valued at $871,000 after buying an additional 597 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its position in Intrexon Corporation by 21.6% in the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 1,305 shares in the last quarter. Hedge funds and other institutional investors own 82.11% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/11/intrexon-corporation-xon-given-average-rating-of-hold-by-brokerages.html.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.